{"id":"NCT01778023","sponsor":"Novo Nordisk A/S","briefTitle":"Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature","officialTitle":"A 12-month, Open-labelled, Randomised, Parallel-group, Multi-centre, Interventional Trial to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone (hGH) (Norditropin® Nordilet®) Therapy on Height Velocity (Ht-V) in Patients With Idiopathic Short Stature in Korea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01-17","primaryCompletion":"2014-12-17","completion":"2014-12-17","firstPosted":"2013-01-29","resultsPosted":"2016-10-05","lastUpdate":"2017-06-02"},"enrollment":54,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Growth Disorder","Idiopathic Short Stature"],"interventions":[{"type":"DRUG","name":"somatropin","otherNames":[]}],"arms":[{"label":"hGH:12months treatment","type":"EXPERIMENTAL"},{"label":"hGH: 6 month un-treatment + 6 month treatment","type":"ACTIVE_COMPARATOR"}],"summary":"This trial is conducted in Asia. The aim of this trial is to evaluate the efficacy and safety of recombinant human growth hormone (hGH) in subjects with idiopathic short stature in Korea.","primaryOutcome":{"measure":"Height Velocity (Ht-V)","timeFrame":"After 6 months of treatment","effectByArm":[{"arm":"Group A: 12-month GH Treatment","deltaMin":12.02,"sd":0.29},{"arm":"Group B: 6-month Untreated + 6-month GH Treatment","deltaMin":6.87,"sd":0.43}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":8,"countries":["South Korea"]},"refs":{"pmids":["32595770"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":36},"commonTop":["Nasopharyngitis","Upper respiratory tract","Influenza","Urticaria","Pyrexia"]}}